To get the latest experience from our website, please upgrade your browser.
After critics accused Johnson & Johnson and Bayer of hiding data in clinical trials for their blockbuster blood thinner Xarelto (rivaroxaban), the U.S. Food and Drug Administration said the drug [...]
Johnson & Johnson’s Janssen Pharmaceuticals knew about a faulty device and data in a Xarelto (rivaroxaban) regulatory trial that suggests they put participants at risk, The BMJ reports. Janssen withheld [...]
Proton-pump inhibitors (PPIs) that treat acid reflux and heartburn may increase the risk for loss of brain function and fluid buildup in the abdomen, a study found. Nexium, Prilosec and [...]
More than half of patients with gastrointestinal (GI) bleeding receive acid reflux drugs called proton pump inhibitors (PPIs) even when guidelines discourage their use, according to a study. University of [...]
The U.S. Food and Drug Administration released a safety communication informing the public of stronger kidney injury warning labels on SGLT2 inhibitors that treat Type 2 diabetes, including J&J’s Invokana/Invokamet [...]
New research suggests that popular heartburn drugs called proton pump inhibitors (PPIs) such as Prevacid (lansoprazole), Prilosec (omeprazole) and Nexium (esomeprazole) may damage arteries leading to an increased risk of [...]